The combination of NHS-IL12 and bintrafusp alfa elicited significant tumor homing of effector memory CD8+ T cells, tumor-specific immunity, increased survival, and anti-metastatic effects and development of protective immune memory (45, 46). The gene discussed is CD8A; the disease is neoplasm.